Metabolic · Amylin receptor agonist
Cagrilintide
- Drug class
- Amylin receptor agonist
- Status
- Compounded (503A)
- Also known as
- AM833, CagriSema (combination)
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What Cagrilintide is studied for
- Chronic weight management (with or without semaglutide)
- Appetite regulation and satiety
- CagriSema combination therapy (phase 3)
Mechanism of action
Long-acting analog of human amylin (pramlintide-class). Activates amylin receptors in the hindbrain to slow gastric emptying, suppress glucagon, and increase satiety — complementary to GLP-1 pathways.
Frequently asked questions
What is CagriSema?
CagriSema is the fixed-dose combination of cagrilintide + semaglutide (Novo Nordisk). Phase 3 REDEFINE trials report ~20–22% average weight loss, exceeding semaglutide alone.
Is cagrilintide available on its own?
It is not yet FDA-approved as a stand-alone product. Phase 3 trials are ongoing; expected regulatory submission 2026–2027.
Side effects?
Similar GI profile to other incretins — nausea, vomiting, diarrhea — generally well tolerated when titrated.
Related peptides in Metabolic
SemaglutideGLP-1 for weight, appetite, and metabolic health.TirzepatideDual GLP-1 / GIP for next-generation metabolic care.RetatrutideNext-generation triple agonist (GLP-1 / GIP / glucagon) in active research.AOD-9604hGH fragment targeting fat metabolism without affecting IGF-1.AICARAMPK activator studied for endurance and metabolic efficiency.HGH Fragment 176-191GH fragment studied for fat metabolism without affecting blood sugar or IGF-1.